Background and Aims: Anal fistula plug [AFP] is a bioabsorbable bioprosthesis used in ano-perineal fistula treatment. We aimed to assess efficacy and safety of AFP in fistulising ano-perineal Crohn's disease [FAP-CD] Conclusion: AFP is not more effective than seton removal alone to achieve FAP-CD closure.
Introduction
In population-based studies, ano-perineal fistulas occur in approximately 30% of Crohn's disease [CD] patients and are more frequently associated with colorectal involvement.
1,2 They represent a major therapeutic issue and impair quality of life with an increased risk of faecal incontinence, 3 faecal diversion, 4 and late proctectomy. 5 Medications reported to be of benefit in reducing fistula drainage include metronidazole and ciprofloxacin, 6 immunosuppressive agents such as 6-mercaptopurine/azathioprine, 7 cyclosporine, 8 tacrolimus, 9 thalidomide, 10 and most of all anti-tumour necrosis factor α [TNFα] agents. 11 Since Present's publication on infliximab in 1999, 12 anti-TNF agents have changed the paradigm of perianal CD treatment. 13 However, despite this significant progress, anti-TNF agents are incompletely efficacious: only one-fifth of all patients treated completely heal after 1 year of follow-up. 11, 14 Moreover, even in cases of closure of draining external orifices after anti-TNF therapy, magnetic resonance imaging [MRI] studies demonstrated that fistula tracks persisted in 73% of cases, which can explain the high risk of recurrent fistulas and abscesses. 15 Therefore, alternative therapies are required.
Surgery remains important in the management fistulising anoperineal CD [FAP-CD] . Placement of seton drainage is often needed to prevent further abscess formation. Fistulotomy for very low fistulas may also be used; in severe cases and if the rectal mucosa is not ulcerated, sphincter-sparing techniques such as rectal advancement flap, gracilis interposition, or ligation of the intersphincteric tract [LIFT] have been proposed. 16, 17, 18 In a previous controlled trial of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif [GETAID] , it has been demonstrated that fibrin glue had limited efficacy, with clinical remission in 38% at Week 8 compared with 16% in the control group [p < 0.05]. Moreover, the benefit was not significant for patients with complex fistulas, with only 25% achieving closure. 19 More recently, anal fistula plug [AFP] was proposed to achieve closure of fistula tracts. AFP [Surgisis AFP ®] is a collagen bio-prosthetic device made with lyophilised porcine small intestine submucosa. This material has inherent resistance to infection, produces no foreign body or giant cell reaction, and becomes repopulated with host cell tissue, promoting healing processes to obliterate permanently the fistula tract over a period of 3 months. 20 It is supposed that in addition to suturing the plug securely at the primary opening, insertion of a conical plug into the high-pressure area of the fistula produces a mechanically stable system promoting healing. Promising results have been reported in cryptoglandular fistulas, with 83% of efficacy in an open study, 21 and 80% in a non-controlled trial conducted in 30 patients with CD. 22 The aim of the present study was to evaluate efficacy and safety of AFP in the treatment of FAP-CD by a controlled trial. 
Methods

Trial design
Participants
Patients eligible for inclusion into the trial were at least 18 years old and had CD that had been confirmed by endoscopy and histology. The Crohn's Disease Activity Index [CDAI] had to be 250 or less. Patients had at least one active ano-perineal fistula track [between the anus or low rectum and the perineum or vulva] for at least 2 months with seton drainage for at least 1 month. Treatments with azathioprine, 6-mercaptopurine, methotrexate, thalidomide, or anti-TNF were permitted providing the dose was stable for more than 3 months, as well as treatment with aminosalicylates at a stable dose for more than 1 month. Oral corticosteroids were tolerated given at stable dose for at least 2 weeks at equal or less than 15 mg/day equivalent prednisone or 6 mg/day budesonide. Patients were not eligible for inclusion if they fulfilled at least one of the following conditions: anal abscess [defined by collection ≥ 3 mm assessed by MRI within the previous month], recto-vaginal fistula, anal or rectal stricture [if dilation could not allow anal retractor insertion to perform plug suture at the internal opening], anal surgery within the past month, rectovaginal fistula, severe proctitis [ulcerations extending over ≥ 10% of rectal mucosa], corticosteroids > 15 mg/day or budesonide > 6 mg/day, anti-TNF started in the past 6 months or with dose and/ or interval modification in the past two administrations, ciclosporin or tacrolimus in the past 3 months, previous use of AFP for FAP-CD, pregnancy, or refusal to receive a porcine device.
Assignment
Patients were randomly assigned to have either AFP [AFP group] or observation after seton removal [control group]. Randomisation was centralised using permutations tables in a ratio 1:1, stratified both on centre and on stratum, predefined as simple or complex fistula. According to AGA classification, complex fistulas are fistulas with multiple tracts, fistulas with a large ulcer [> 5 mm] at the internal opening, and fistulas with an ano-vaginal tract. The numbers were allocated sequentially in the order of enrolment. Patients could not be included twice in the study. After obtaining informed consent, investigators used a specific form sent by fax, which assigned the eligible patient to the next randomisation number for the centre and stratum concerned.
AFP group
Either a surgeon or a proctologist carried out the procedure in an operating theatre under aseptic conditions. Enema [Normacol;
Norgine Pharma, France] was administered before the procedure. Broad-spectrum parenteral antibiotic was given on induction of anaesthesia according to French Society of Anaesthesia and Reanimation protocols. The fistula tract was thoroughly rinsed with hydrogen peroxide and saline. All setons were removed during the procedure.
The AFP was hydrated for 2 min in room-temperature saline. When the seton was cut, it was used to pull the plug into the tract. A 2-0 vicryl suture was tied to the tip of the plug, secured to the seton, and the plug was pulled tip first into the internal opening, until resistance was encountered. The excess plug material was trimmed at the level of primary opening, and the plug was buried into the primary opening using a figure-of-eight or X 2-0 vicryl suture, which was inserted deep to the internal sphincter muscle to avoid extrusion of the plug. The head of the plug was optimally covered by at least mucosa and submucosa. Care was taken not to occlude the secondary opening to allow drainage of exudate and to avoid a closed system. In case of multiple fistulous tracks, several plugs could be inserted. All patients were advised to avoid any strenuous activity and to observe sexual abstinence during 2 weeks.
Control group
Patients in the control group underwent a clinical examination with setons removal without general anaesthesia. At Week 12, AFP was proposed to all patients who did not achieve clinical remission, whatever the treatment they were assigned by randomisation.
Follow-up and evaluation variables
The medical history with past and current medications was recorded at study baseline. 15 
Sample size and statistical analysis
The sample size calculation was based on the assumption that AFP would be superior to seton removal alone. A minimum of 102 patients [51/arm] would provide a 90% power to detect a 30% difference in remission rate between AFP and control groups, based on a two-sided test with type I error of 5%, from the 20% assumed rate of remission in controls. 19 Analysis was made on an intent-to-treat basis. Categorical variables were described globally or per treatment group using frequencies and percentages, and continuous variables were expressed using the median and interquartile range [IQR] .
For 
Access to study data
All authors had access to the study data and reviewed and approved the final manuscript.
Results
The flowchart diagram of the study is shown in Figure 1 . A total of 106 patients with FAP-CD were randomised: 54 patients allocated to the AFP group [including 39 with simple fistula stratum] and 52 patients to the control group [including 39 with simple fistula stratum]. Characteristics of the patients are shown in Table 1 . All characteristics were well balanced between the two treatment groups. Among the 70 patients who did not achieve remission at Week 12, 14/31 and 34/39 initially allocated to the and the seton removal alone groups, respectively, were treated using AFP [ Figure 1 
Primary end point
Secondary end points
There was no evidence that clinical remission and clinical response rates differed between the two groups at Weeks 4 and 8 and Months 6 and 12 [ Table 2 ]. The time course of PDAI scores according to randomisation group is displayed in Figure 2 
Discussion
The present study, which is the first randomised controlled trial evaluating plug insertion in FAP-CD patients, failed to demonstrate that AFP insertion was more effective than seton removal alone in patients having at least one fistula tract draining for more than 1 month. AFP has been used in the management of anal fistulas, with interesting results reported since 2006. It has been considered as an attractive option in FAP-CD patients where the risk of incontinence associated with fistulotomy contraindicates this procedure. Repopulated with host cell tissue, the AFP is supposed to promote healing processes to obliterate the fistula tract. From a theoretical point of view, this device is a solid bioprosthetic material, less likely than fibrin glue to be expelled from fistula tract. Another presumed advantage of the AFP is that the operative technique requires suturing of the device to the internal anal sphincter at the internal opening, to keep the material in place, allowing time for colonisation with host cells and healing. Since the enthusiastic initial reports were published, several trials have been performed with AFP with more disappointing results. The failure rates found in the Remission at week 12 12 Not in remission at week 12 39 Cross over Treated 34
Success 10
Non success 21
Not analysed 3
Non treated 5 literature for the AFP vary a lot and range from 12% to 87%. 38 The proportion of patients achieving fistula closure varied widely between studies for non-CD, ranging from 0. Only two randomised controlled studies have been published for AFP in non-CD fistulas. They compared AFP with mucosal advancement flap. 39, 40 In the first study, a large number of recurrences in the fistula plug group led to premature closure of the trial. 39 The second study, which included 60 patients with a follow-up of 11 months, showed a recurrence rate of 71% and 52% in the AFP group and the mucosal advancement flap group, respectively (not statistically significant). 40 The present controlled trial did not confirm those preliminary promising results. Among the hypotheses to explain such results, smouldering sepsis is not relevant as patients had had MRI within the past month before inclusion and were excluded if a collection ≥ 3 mm was assessed by this examination. Several other explanations may be provided. First, we may wonder if variables such as operative technique or perioperative care could influence the probability of success or failure associated with the AFP. The plug extrusion is a complication felt by many to be a 'learning curve issue' for the surgeon. However, surgeons in our study were experienced in anal fistula surgery; all plugs were inserted according to the guidelines presented in a previous consensus meeting. 41 The dislodgement rate was 10%, a proportion comparable to the literature's rates of 8.7% reported in O'Riordan's review. 42 Second, we may have included particularly refractory disease. Part of our patients had persistent ano-perineal fistulas while they were treated with biologicals and, for the majority, on immunosuppressant therapy. Many had had a previous attempt to close their fistulas, including with fibrin glue injection. We also observed a high rate of abscesses that occurred in 11 and 10 patients in the plug and control groups, respectively. For comparison, in our previous trial with fibrin glue, only one abscess occurred in the control group. 19 Finally, our study has some limitations. First, the sample size was computed in order to detect a large difference in response rate, from 20% in the control up to 50% in the AFP arm. Actually, fistula closure at Week 12 was achieved in 31.5% in the AFP group vs 23% in the control group, and this exemplifies the over-optimistic assumed effect of AFP when the trial was scheduled. Of note, the 
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response rate varied across centres, illustrating that such a surgical procedure may be difficult to apply. Our study was not blinded, as the investigator performed the end point evaluation, which could have induced bias. The primary end point of 12 weeks could be considered as a relatively short follow-up. However, we chose this end point because in our previous trial we demonstrated efficacy of fibrin glue at Week 8 in FAP-CD, which is an even shorter period. 19 Finally, although there was no statistical evidence of any heterogeneity in treatment effect, the potential interest of the AFP could be increased in cases of complex fistula, so that further trials should focus on such a population.
To conclude, AFP should not be considered for ano-perineal fistulas] closure in CD as it is not more effective than seton removal alone. Other procedures should be proposed, such as fibrin glue injection especially in single fistula, or mucosal advancement flap in single or complex fistulas, even if they have limited efficacy. New techniques like stem cells injections 43 44 or ligation of the intersphincteric tract, 45 that are still under evaluation, should be assessed by adequate randomised controlled studies. 
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